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The aim of this study was to compare and externally validate risk scores developed to predict 
incident colorectal cancer (CRC) that include common genetic variants (single nucleotide 
polymorphisms, SNPs), with or without established lifestyle/environmental (questionnaire-
based/classical/phenotypic) risk factors. We externally validated 23 risk models from a 
previous systematic review in 443,888 participants aged 37-73 from the UK Biobank cohort 
who had 6 year prospective follow-up, no prior history of CRC and data for incidence of 
CRC through linkage to national cancer registries. There were 2,679 (0.6%) cases of incident 
CRC. We assessed model discrimination using the Area Under the Curve (AUC) and relative 
risk calibration. The AUC of models including only SNPs increased with the number of 
included SNPs and was similar in men and women: the model by Huyghe with 120 SNPs had 
the highest AUC of 0.62(95%CI 0.59-0.64) in women and 0.64(95%CI 0.61-0.66) in men.  
Adding phenotypic risk factors without age improved discrimination in men but not in 
women. Adding phenotypic risk factors and age increased discrimination in all cases 
(p<0.05), with the best performing models including SNPs, phenotypic risk factors and age 
having AUCs between 0.64-0.67 in women and 0.67-0.71 in men. Relative risk calibration 
varied substantially across the models. Among middle-aged people in the UK, existing 
polygenic risk scores discriminate moderately well between those who do and do not develop 
colorectal cancer over six years.  Consideration should be given to exploring the feasibility of 







Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies worldwide. 
Incidence is rising in many countries[1], particularly among younger individuals[2]. There is 
good evidence that population screening reduces CRC incidence and mortality[3–6], and in 
most countries with a high frequency of CRC screening has now been introduced[7]. 
As for other cancers, including breast[8], lung[9] and ovarian[10], there is increasing interest 
in using risk models to predict who is at highest and lowest risk of developing CRC and 
guide screening decisions. By identifying those who are more likely to benefit from screening 
and inviting them earlier, more frequently or for different screening tests, this approach has 
the potential to increase net benefit of CRC screening at lower cost. 
We, and others, have previously shown that several risk models based on phenotypic 
variables have relatively good discrimination in external validation and could, therefore, be 
used for this purpose[11,12]. Advances in genetic research and technology mean that it will 
soon be possible to provide a relatively cheap, quick and accurate assessment of an 
individual’s genetic risk of CRC. Models incorporating genetic variables may, therefore, be 
simpler to implement. Previous work has also shown that using such genetic information to 
stratify screening has the potential to improve efficiency of screening[13] and reduce the 
number of individuals screened while still detecting as many cases[14]. Of the 29 models 
identified in our review, however, many had only been assessed in the development 
population. The comparative performances of these models in the same population and the 
added value of including phenotypic risk factors together with genetic risk factors in the UK 
population are not known.  
In order to inform future risk stratified screening approaches in the UK, in this study we 
assessed the performance of risk scores that include common genetic variants and predict 
future CRC, with or without phenotypic risk factors, in a cohort of 443,888 individuals. 
The identification of genetic risk factors for common diseases has been disproportionately 
focused in white / European populations[15]. Consequently, there is concern that risk 
stratified screening in the UK could increase inequalities in health. We therefore also 
additionally assessed the performance of genetic risk scores among ethnic minorities in an 
exploratory analysis. 
 
MATERIALS AND METHODS 
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We performed an external validation of genetic (GRS) and combined GRS plus phenotypic 
risk models for prediction of incident CRC, following the TRIPOD (Transparent Reporting of 
a multivariable prediction model for Individual Prognosis Or Diagnosis) guideline[16]. 
 
Validation cohort 
For our validation cohort we used UK Biobank, the largest population-based cohort in the 
UK[17]. Women and men aged 37-73 years, who were registered with the National Health 
Service and lived within approximately 25 miles of one of 22 study assessment centres across 
the UK, were invited to participate between 2006-2011. From 9.2 million invitations 503,325 
were recruited (5.5%) and attended a baseline assessment when data were collected using 
touchscreen questionnaires, interviews and physical measurements, and blood samples 
provided. 
 
CRC diagnosis in the validation cohort 
CRC cancer diagnosis is recorded for UK Biobank participants through linkage to national 
cancer registries.  The most recent cancer record in UK Biobank has a diagnosis date of 27th 
October 2016.  We censored all follow up at 31st March 2016 to ensure that late registrations 
were not missed.  We included 451,171 out of 502,326 UK Biobank participants who had 6 
years of complete follow up from date of baseline assessment until 31st March 2016, 
excluding people who had less than 6 years follow up but including those who died during 
the follow-up period.  For this validation we identified CRC with the following diagnosis 
codes: ICD9 153.0-153.9, 154.0, 154.1 and 154.8 and ICD10 C18.0-C18.9, C19, C20 and 
C21.8.  We excluded from all analyses 2,489 participants who had a diagnosis of CRC prior 
to the baseline assessment.  659 included participants had a CRC diagnosis after the end of 
the included 6 years of follow-up and are included in this analysis as non-cancer cases.  As 
participants with previous colorectal polyps, n=1,473, or a diagnosis of inflammatory bowel 
disease (IBD), n=4,231, would likely be in surveillance programmes, we also excluded 
individuals with a self-reported history at baseline. Of the 443,888 participants included in 
our primary analysis there were 2,679 (0.6%) cases of incident CRC within the complete 6 
year follow-up period. 
The only exception to this was for the validation of one model (Huyghe et al.) [18] for which 
UK Biobank CRC cases from September 2014 and earlier formed part of the original analysis 
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data set for this risk prediction model.  For this model we included all UK Biobank 
participants without a history of colorectal polyps or IBD who were still alive and without a 
CRC diagnosis on 30th September 2014, and followed them up until 31st March 2016.  For 
this model we included 482,089 participants and 842 cases of CRC in the 18 month follow up 
period. 
 
Selection of risk prediction models 
In our systematic review[19] we identified 29 genetic only (GRS) or combined GRS and 
phenotypic models for CRC from 20 publications. After contacting authors if insufficient 
data were provided in the original publications, we excluded 11 models because either details 
of the risk alleles were not available[20,21], the relative risk parameters associated with  
predictors included in the model were not published[22–24], they included variables not 
available in UK Biobank[25–27] or biochemical risk factors[28], or if the model was 
developed separately for proximal and distal colon and rectal cancers[29].  
After these exclusions, we included 17 models from our systematic review[18,22,24,30–39].  
We additionally separately included the GRS component from five of these models[29–
31,36,39] that were developed only as combined GRS plus phenotypic models.  For the Hsu 
model[29], only the GRS was included as the GRS plus phenotypic versions were developed 
separately for proximal and distal colon, and rectal cancers.  From the Smith publication we 
considered only the model incorporating the Wells phenotypic risk score[40].  We further 
included the GRS plus phenotypic risk model developed by Jenkins et al.,[41] that was 
published separately from the genes-alone GRS developed by the same team.  
Details of these 23 models, including the study design, development method and the risk 
factors used in the prediction of CRC risk for each are given in Table 1.  Fourteen models 
were GRSs including only SNPs, four included SNPs plus phenotypic factors, but not age, 
and five a combination of SNPs, phenotypic factors and age.   
 
Genotyping 
For all UK Biobank participants blood samples were genotyped using Affymetrix UK 
BiLEVE Axiom array and Affymetrix UK Biobank Axiom array and imputed to the 
combined 1000 Genomes Project v.3 and UK10K reference panels using SHAPEIT3 and 
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IMPUTE3. The lowest imputation info score for the SNPs used in these analyses was 
0.86[42].  
 
Coding of risk models in UK Biobank 
Full details of the definition of each risk factor and how we operationalised them in the UK 
Biobank dataset and handled missing data are given in Supplementary Tables 1 (SNPs) and 2 
(phenotypic risk factors).  
 
Ethnicity 
Race/ethnicity, hereafter ethnicity, as this is the terminology used in the UK, was quantified 
using categories from the UK Office of National Statistics 2001 16 group classification[43], 
summarised in 5 groups; White/European, (response options: 
English/Welsh/Scottish/Northern Irish/British, Irish, and Any other White background), 
Mixed (White and Black Caribbean, White and Black African, White and Asian, Any other 
Mixed/multiple ethnic background), South Asian (Indian, Pakistani, Bangladeshi, Any other 
Asian background), Black (African, Caribbean,  Any other Black/African/Caribbean 
background), Other (Chinese, Any other ethnic group). 
 
Analysis 
For all of the models, we computed the predicted risk score for developing CRC for each 
participant using data collected at baseline assessment. Only one score (Dunlop et al) 
predicted an absolute risk of CRC over a specific time frame, all other scores predicted 
relative, rather than absolute risk (RR). 
We assessed model performance in terms of discrimination and relative risk calibration. For 
GRS scores we calculated standardized versions of the scores and estimated the odds ratio 
(OR) for CRC associated with a 1 standard deviation (SD) increase in the standardized risk 
scores as a measure of discrimination; discrimination was further assessed using the area 
under the curve (AUC) for all models. 
Calibration was assessed graphically by comparing the expected with observed relative risk 
of developing CRC over the six-year follow-up period.  We stratified our analysis cohort by 
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deciles of predicted relative risk (with decile 5 as the baseline). The observed relative risk in 
each decile was calculated as the proportion of cases in the decile divided by the proportion 
of cases in the entire sample, divided by the same estimate in decile 5. The expected RR in 
each decile was calculated as the geometric mean (because log RR rather than RR is normally 
distributed) of the predicted RR in the decile divided by the mean predicted RR in decile 5. 
We also calculated sensitivity, specificity, positive and negative likelihood ratios (LR+ and 
LR-) and the positive and negative predictive values (PPV and NPV) using a cut-off value for 
each risk score chosen such that 10% of the population had values above the cut-off; the 
procedure was then repeated using cut-offs for which 20%, 80% and 90% had values above 
the cut-off.   
In a further analysis we compared the performance of the GRS scores with models 
additionally including age (categorized as above and below age 60, the current UK CRC 
screening threshold age) and family history in order to provide a preliminary evaluation to 
inform whether there would be a benefit to incorporate GRS into clinical practice. 
Our first analysis considering the discrimination of GRSs alone was stratified by ethnicity, 
and considered all UK Biobank participants without stratification by sex, because of the 
relatively small numbers of people reporting non-white/European ethnicity in UK Biobank.  
Discrimination using AUC and RR calibration were assessed among people from all ethnic 
backgrounds and stratified by sex. All analyses were carried out in Stata 15 (StataCorp 2017). 
 
Missing data 
For our primary analyses we used a “complete-case” approach including only those 
individuals for whom all of the risk factors in a particular prediction model were available.  
The sample size is therefore consistent across all genetic models, except for the model of 
Wang et al (that incorporated genotypes which, in a small number of samples, could not be 
ascertained from imputed allele counts), and the model of Huyghe et al. as described above, 
but sample sizes varied between models which included non-genetic risk factors, as the 
amount of missing data for phenotypic risk factors – particularly dietary ones – varied 





We primarily focused our sensitivity analyses on areas not previously addressed[11] and 
those particularly relevant to genetic risk models.  Accordingly, we compared the 
performance of risk scores after excluding people with high degree of relatedness to other 
cohort members (people with >10 relatives, estimated using genetic data), and randomly 
excluding one of each pair of first degree relatives.  We also compared the performance in a 
cohort excluding all individuals with any cancer diagnosis prior to baseline. For both these 
analyses we followed the methods from previous work[44].  We carried out an additional 
sensitivity analysis comparing discrimination for the GRS models among people 60 and 
under, and over 60.  In a further sensitivity analysis we excluded all people with a history of 
colonoscopy at baseline. 
For GRS plus phenotypic models we carried out a further sensitivity analysis restricting our 
sample for the GRS models to those individuals in whom the GRS plus phenotypic version of 
the risk score could be estimated (i.e. only among those individuals with complete phenotype 
characterization for each score).  
For the Huyghe model[18] we carried out a further sensitivity analysis including the 6 years 
of follow used for the other models. . For the model from Abe[30] we additionally compared 




The characteristics of the study population are shown in Supplementary Table 4. Compared 
to those who did not develop CRC, those who did were more likely to be male, older, and 
have a family history of CRC. Although the number of SNPs varied across models, the 
median number of risk alleles among CRC cases was typically one higher than among those 
who did not develop cancer. 
 
Discrimination 
GRS discrimination, stratified by ethnicity 
Among the 441,141 participants who self-reported their ethnicity, 419,579 (95%) were 
White. Mean standardized GRS among people with CRC varied between 0.02 and 0.45 in the 
whole validation cohort, and among the whole cohort varied from -1.44 to 0.85 when 
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stratified by ethnicity (Supplementary table 5).  The Huyghe GRS had the highest OR per 
1SD of GRS, 1.60 (1.50-1.72) among all UK Biobank participants and 1.60 (1.50-1.72) 
among people reporting a white/European ethnic background.  Five of the GRSs showed 
some discriminative ability among people with non-white ethnicity[22,24,29,31,35] (Table 
2).   
 
GRS discrimination, stratified by sex 
Figure 1 and Supplementary Table 6 show the discrimination, measured by AUC, for all 
models in the whole UK Biobank population, stratified by sex. Discrimination for the 14 
GRS models is similar in men and women and ranges from 0.50 to 0.63. The AUC increased 
with the number of SNPs included within the risk models (Figure 2), with the 120-SNP 
model by Huyghe having the highest AUC of 0.62 (95% CI 0.59-0.64) in women and 0.64 
(95% CI 0.61-0.66) in men.  In general, the GRSs based on newer genome-wide association 
(GWA) studies (GWA) also performed better than those based on candidate genes or older 
GWA studies. These analyses stratified by White-European/non-White-European ethnicity 
are presented in Supplementary Table 7. 
 
< insert figure 1 about here > 
 
< insert figure 2 about here > 
 
GRS-plus phenotype discrimination, stratified by sex 
Among the four models that incorporated both genetic and phenotypic risk factors but not 
age[31,34,38,41], adding phenotypic factors, including BMI, smoking, family history, 
alcohol intake, red meat intake and physical activity, either did not change the AUC[31,34] or 
reduced it[38,41] in women. In men, however, the AUC improved from 0.55 (0.54-0.57) to 
0.59 (0.57-0.6) with the addition of smoking, BMI, alcohol, fibre intake, red meat intake and 
physical activity in the Yarnall model[34] and from 0.55 (0.54-0.57) to 0.58 (0.56-0.59) with 
the addition of family history, BMI, alcohol intake, physical exercise, red meat and vegetable 
intake and NSAIDs/aspirin use in the Ibanez-Sanz model[38].  
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Considering only people in whom it was possible to calculate a risk-score based on both the 
GRS and GRS plus phenotypic versions of the same models confirmed these differences, 
with significant (p<0.05) improvements in AUC observed only with the addition of 
phenotypic risk factors in the Yarnall and Ibanez-Sanz models in men (Supplementary Table 
8).  
By comparison, the discrimination of models including age was greater (p<0.05) than for 
GRSs alone for all models in both women and men, with a relatively greater improvement in 
performance in men than women (Figure 1). The models with highest AUC were those 
developed by Abe, Hosono, Dunlop and Smith[24,30,32,36], with AUCs between 0.67-0.71 
in men and 0.64-0.67 in women.  
The sensitivity, likelihood ratios and PPV and NPV for thresholds at which varying 
percentages of the population are classified as high risk are presented in full in 
Supplementary Tables 9 and 10.  Within the 10% of the population with the highest risk, the 
top performing GRS[18] identified 18.6% of women and 22.3% of men who went on to 
develop CRC. Among those with the highest 20% risk, this increased to 30.7% for women 
and 35.7% for men. For the four best performing GRS plus phenotypic models that also 
included age[24,30,32,36], in women the top 10% of the population included between 19.7% 
and 20.7% of those who went on to develop CRC and the top 20% 33.8% to 38.1%. In men, 
the corresponding values are 21.1% to 26.9% and 38.2% to 47.9%. The NPVs were high and 
comparable (>99.3) for all models. 
 
Calibration 
Results from the relative risk calibration are presented for women and men in Figures 3 and 4 
and Supplementary Tables 11 and 12. There is variation in calibration across models, with 
some models having very poor calibration.  There is a consistent pattern that models tend to 
over-estimate relative risk at higher levels of risk. Calibration did not substantially improve in 
models based on a GRS plus phenotypic risk factors compared with those that include only a 
GRS, except for those which incorporated age.  
 




< insert figure 4 about here > 
 
The additional analysis comparing the AUC of models incorporating each GRS, age and 
family history, with age and family history alone found that  for all models except Wang 
adding the GRS increased the AUC by between 0.01 and 0.03 (Supplementary Table 13), i.e. 
reducing between 3-9% of the remaining error. 
 
Sensitivity analyses 
The results from the all the other sensitivity analyses were consistent with the main analysis 




This is, to our knowledge, the first external validation to use a single cohort to directly 
compare multiple published risk prediction models for CRC that include common genetic 
markers. It shows that genetic information alone discriminates moderately well between those 
who do and do not develop CRC over a six year period.   The best performing GRS by 
Huyghe et al.,[18] had an AUC of 0.62 in women and 0.64 in men and OR per 1SD of 1.60, 
comparable with polygenic risk scores in breast cancer (AUC 0.63 (95% CI 0.62-0.64), OR 
per 1SD 1.49-1.71[45]) and coronary artery disease (0.62 (95% CI: 0.62 to 0.63)[46]) and 
better than risk models including phenotypic risk factors without age[11,24]. 
In contrast to risk models incorporating phenotypic risk markers for which performance in 
men is better than in women[11,12], the performance of GRSs was equivalent. Consistent 
with this, adding phenotypic risk factors without age to a GRS improved the AUC in men but 
not in women, with the best performing models including SNPs, phenotypic risk factors and 
age having AUCs between 0.67-0.71 in men and 0.64-0.67 in women.  
The potential impacts of incorporating these risk scores into practice are best appreciated by 
the differences in risk classification between the models. Our previous work using UK 
Biobank identified that using the current age-based English bowel cancer screening threshold 
of 60 years to identify the population at high risk for CRC and then random sampling to 
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account for ties, targeting people in the top 10% of risk would identify 17% of men and 16% 
of women who developed CRC[11]. The equivalent proportions using the Huyghe model 
with the highest discrimination for genetic risk factors alone in this study would be 22% for 
men and 19% for women, representing an increase in detection of 2-5% of cases for the same 
number of people screened. This is consistent with an analysis by Jenkins et al.,[13] who 
showed that, in a hypothetical population based on the Australian population in 2011, inviting 
individuals for screening based on their genetic risk rather than all those aged between 50 and 
74 would result in a 3.1% overall improved efficiency.  
 
Strengths and Limitations 
The main strengths of this analysis are the use of a large cohort with nearly 3 million person-
years of follow-up, comprehensive phenotyping and genotyping and linkage to national 
cancer registries, and the inclusion of 23 risk models identified from a systematic review[19]. 
We were not only able to perform the largest external validation to date of multiple CRC risk 
models in a single population but were also able to compare the performance of models 
including only SNPs to those including SNPs plus phenotypic risk factors with or without age 
and family history.   
However, despite its many strengths, the UK Biobank, has a number of limitations. In 
particular, the response rate to invitations to take part was only 5.5%[17]. As a result, 
participants are more likely to be older, to be female, and to live in less socioeconomically 
deprived areas than non-participants; incidence rates of CRC are also lower than in the 
general population[47].  We limited the effect of this ‘healthy volunteer’ bias by restricting 
our analyses to relative risk and discrimination. Analysis of SNP data may also potentially be 
less likely to be confounded by this ‘healthy volunteer’ bias than models including 
phenotypic risk factors as well.  The large variation in age at baseline assessment also means 
that age has a disproportionately large impact on CRC risk compared other phenotypic 
measures.  A third limitation is that CRC cases registered at Scottish cancer registries may 
not all be complete after 31/03/2015.  This may impact up to 10% of the cohort and result in 
an underestimate of CRC risk overall. Finally, CRC screening at age 60 in the UK was rolled 
out during the period of recruitment to UK Biobank.  Some, but not all members of the cohort 
will therefore have participated in the national screening programme during this period.  Our 
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sensitivity analysis excluding people with a history of colonoscopy at baseline, however, did 
not change the findings of this analysis. 
Although similar to the 2011 UK Census[47], the predominantly White population within the 
UK Biobank cohort also means that AUC estimates when restricted to participants from 
ethnic minorities have wide confidence intervals and assessing the model performance is 
challenging.  Any small differences between White and non-White populations should, 
therefore, not be over-interpreted.  In our primary analysis we have applied the GRS/GRS 
plus phenotypic risk models to everyone, regardless of the population in which they were 
developed. We acknowledge the issue of population stratification leading to spurious 
associations between genetic risk factors and disease when people from diverse ethnicities are 
analysed in the same cohort.  Nonetheless, in practice any policy for developing stratified 
screening will be applied across the whole country; these results present the performance of 
these models in this scenario.   
There are also limitations with our analysis. Firstly, we excluded two models identified from 
our systematic review because they included variables not present in UK Biobank and we had 
to derive proxy variables if there were no exact matches for variables included in the risk 
models. We also only assessed RR calibration. Although this does not allow us to assess how 
closely the predicted absolute risk matches the observed absolute risk, it illustrates the 
variation in calibration across the models and highlights that models would need to be 
calibrated to the population in which they are going to be used.   
 
Comparison with existing literature 
When compared with findings of validation studies in external populations or non-random 
split samples[19], our results for discrimination are similar for the genetic risk models by 
Dunlop, Ibanez-Sanz and Smith, but lower for the genetic risk models by Hosono and Xin. 
The lower discrimination seen in this cohort for the Hosono and Xin models likely reflects 
differences in the ethnicity of the populations: the model by Hosono was developed using 
logistic regression and subsequently validated in a Japanese cohort and the model by Xin 
used published GWAS studies from European and Asian populations and validated the model 
in a Chinese cohort. Our results for the Smith model that combined genetic risk factors with 
phenotypic risk factors and age from the model by Wells were also consistent with the 
evaluation of that model in an earlier release of UK Biobank data. For the remaining three 
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models (Abe, Dunlop and Hosono) our results showed better discrimination. In all three cases 
the previous validation studies had been performed in case-control studies matched by age, 
effectively removing the effect of age from the models, and highlighting the strength of age 
as a risk factor. This effect of age may also explain why Smith et al. found in UK Biobank 
that addition of a GRS to either the models by Taylor[48] or Wells[40], both of which include 
age, did not improve discrimination and did not result in a substantive change in the predicted 
probability for the majority of participants[24].  
 
Conclusions and implications for future research 
This study shows that existing GRSs are able to discriminate moderately well between those 
who develop CRC and those that do not and, unlike phenotypic risk scores, they do not 
perform differentially in men and women. Genetic risk scores may also be easier to 
implement than phenotypic risk scores as they do not change over time and are not associated 
with the same degree of measurement error and bias as phenotypic risk factors. With on-
going GWAS studies and increasingly comprehensive imputation panels that allow for 
improved low-frequency and rare genetic variant imputation, it is expected that new SNPs 
associated with CRC will be identified in the future[35,49]. Alongside these efforts to 
identify further SNPs, future studies are needed to develop and validate GRSs in non-
European populations and model the potential impact of incorporating them into screening 
programmes, as is being done for other cancers[8]. There are a number of other issues that 
also need to be considered before stratified screening based on genetic risk can be 
implemented. These include the need for fundamental changes in the infrastructure and 
mechanisms for genetic data collection, storage and sharing[50], and ethical, legal and social 
considerations such as equity of access to genetic testing, insurance issues, and whether 
screening programmes should exclude people currently eligible as a result of their age on the 
basis of low genetic risk. Further research should focus on these areas as well as modelling 
the potential health benefits and cost effectiveness of implementing stratified genetic risk 
based colorectal cancer screening. By demonstrating the current performance of risk scores 
including genetic risk information in a large UK population, this study supports the need for 
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All data on the risk models are available from the reports or authors of the primary research. 
All key data fields derived for this study and the underlying STATA code used to generate 
the main results of the paper will be made available through the UK Biobank access team 
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Table 1. Details of the development and factors included in each of the risk scores included in validation study 
Author, year Country 














Non-genetic risk factors included in score 
Age Sex FH BMI Smoking Other 




● ● ● ● ● Referral pattern, alcohol 
consumption, regular 
exercise, and dietary 
folate intake 
Dunlop 2013 UK, Canada, 
Australia, USA 
and Germany 
(d) Sweden and 
Finland (v) 
10 Weighted allele 
model weighted by 







Scottish data  
● ● ●    
Frampton 2016 UK (v) 37 Weighted allele 
model weighted by 
published log odds 
●        




●  ● ● ● Referral pattern, alcohol 
consumption, regular 
exercise, dietary folate 
intake 
Hsu 2015 USA and 
Germany (d, v) 
31 Weighted model 
weighted by 
published log-odds 
        




120 Weighted allele 
model weighted by 
study derived 
weights 
●        
Ibanez-Sanz 2017 Spain  
(d, v) 
21 Unweighted allele 
counting model 
(weighted allele 
models weighted by 
published log-odds 
and study derived 




  ● ●  Alcohol use, physical 
exercise, red meat and 
vegetable intake, 
NSAIDs/aspirin use 
Iwasaki 2017 Japan (d, v) 6 Weighted allele 








● Developed in 
men only 




CRC – colorectal cancer, SNP - single-nucleotide polymorphism, BMI – body mass index, NSAID – non-steroidal anti-inflammatory drug, GRS – genetic risk score. d = development; v – validation; 
Jenkins 2016 / 2019 Weighted allele 
model weighted 
by published log 
odds 
49 Weighted allele 
model weighted by 
published log odds 
●    ●    
Jeon 2018 Australia, 
Canada, 
Germany, Israel 
and USA.(d, v) 
63 Weighted allele 










 ● ● Height, education, history 
of type 2 diabetes 
mellitus, alcohol 
consumption, regular 
aspirin use, regular 
NSAID use, smoking, 
intake of fibre, calcium, 
folate, processed meat, 
red meat, fruit, 
vegetables, total-energy, 
physical activity (both) 
HRT (women) 
Smith 2018 UK (d, v) 42 Weighted allele 
model weighted by 
published log odds 






●  ● ● ● Diabetes, multi-vitamin 
usage, years of education, 
alcohol intake, physical 
activity, NSAID usage, 
red meat intake, smoking, 
oestrogen use (women 
only) 
Wang 2013  Taiwan (d, v) 16 Logistic regression / 
GRS based on 
genotypes not alleles 
●        
Xin 2018 China (d, v) 14 Weighted allele 
models weighted by 
published log odds 
and by study derived 
weights 
●        
Yarnall 2013 UK (v) 14 Weighted allele 
model / developed 









   ● ● Alcohol, fibre intake, red 




Table 2. Genetic Risk Score (GRS) discrimination / odds ratio for colorectal cancer per standard deviation increase in 
risk score, stratified by self-reported white / non-white ethnicity  
 














Abe 2017 -0.01 (1.00) 0.16 (0.98) 1.20 (1.15 - 1.25) 1.23 (0.98 - 1.53) 1.18 (1.14 - 1.22) 
Dunlop 2013 0.00 (1.00) 0.22 (0.98) 1.25 (1.20 - 1.30) 1.22 (0.98 - 1.52) 1.25 (1.20 - 1.30) 
Frampton 2016 0.00 (1.00) 0.17 (1.00) 1.18 (1.13 - 1.23) 1.40 (1.12 - 1.76) 1.18 (1.14 - 1.23) 
Hosono 2016 0.00 (1.00) 0.13 (0.97) 1.16 (1.12 - 1.21) 1.10 (0.88 - 1.36) 1.14 (1.10 - 1.19) 
Hsu 2015 -0.01 (1.00) 0.26 (0.98) 1.30 (1.25 - 1.35) 1.27 (1.01 - 1.61) 1.30 (1.25 - 1.35) 
Huyghe 2019 -0.01 (1.00) 0.47 (0.99) 1.60 (1.50 - 1.72) 1.10 (0.73 - 1.65) 1.60 (1.50 - 1.72) 
Ibanez-Sanz 2017 0.00 (1.00) 0.19 (1.00) 1.20 (1.16 - 1.25) 1.28 (1.02 - 1.60) 1.22 (1.17 - 1.26) 
Iwasaki 2017 0.00 (1.00) 0.13 (1.00) 1.15 (1.11 - 1.20) 0.96 (0.75 - 1.21) 1.14 (1.10 - 1.19) 
Jenkins 2016 -0.01 (1.00) 0.23 (0.97) 1.28 (1.23 - 1.33) 1.10 (0.88 - 1.38) 1.26 (1.21 - 1.31) 
Jeon 2018 0.00 (1.00) 0.29 (0.99) 1.33 (1.28 - 1.38) 1.42 (1.13 - 1.79) 1.33 (1.28 - 1.39) 
Smith 2018 -0.01 (1.00) 0.23 (0.98) 1.27 (1.22 - 1.32) 1.39 (1.11 - 1.73) 1.26 (1.22 - 1.31) 
Wang 2013 0.00 (1.00) 0.02 (0.98) 1.01 (0.97 - 1.05) 1.08 (0.85 - 1.36) 1.02 (0.98 - 1.06) 
Xin 2018 0.00 (1.00) 0.13 (1.00) 1.15 (1.11 - 1.20) 1.24 (1.04 - 1.49) 1.14 (1.09 - 1.18) 







TITLES AND LEGENDS TO FIGURES 
Figure 1. Discrimination, measured by the area under the receiver operating characteristic curve (AUC) for 
the risk models in women and men. 
Figure 2. Discrimination (AUC ± 95% CI) of models including genes only plotted against number of SNPs included 
in each model 
Figure 3. Relative risk (RR) calibration in women. 
Figure 4. Relative risk (RR) calibration in men. 
 




